Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Geodrill Announces Record First Quarter 2025 Financial Results (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Silence Therapeutics ADR Representing 3 Ord Shs SLN

Healthcare Biotechnology
Silence Therapeutics plc is a United Kingdom-based biotechnology company. The Company is developing medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes. The Company's mRNAi GOLD (GalNAc Oligonucleotide Discovery) platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence... see more

Recent & Breaking News (NDAQ:SLN)

Silence Therapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights

Business Wire March 13, 2024

Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)

Business Wire March 13, 2024

Silence Therapeutics to Report Fourth Quarter and Full Year 2023 Results on March 13, 2024

Business Wire February 28, 2024

Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 Trial

Business Wire February 23, 2024

Silence Therapeutics Announces Oversubscribed $120 Million Private Placement

Business Wire February 5, 2024

Silence Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Business Wire January 31, 2024

Silence Therapeutics Strengthens Executive Leadership Team with Key Appointments

Business Wire December 1, 2023

Silence Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results

Business Wire November 14, 2023

Silence Therapeutics to Present at Jefferies London Healthcare Conference

Business Wire November 8, 2023

Silence Therapeutics Announces Positive Topline Results from Phase 1 Multiple Dose Study of Zerlasiran in Subjects with High Lipoprotein(a) and Stable Atherosclerotic Cardiovascular Disease

Business Wire November 1, 2023

Silence Therapeutics to Participate in Fireside Chat at Chardan's 7th Annual Genetic Medicines Conference

Business Wire September 26, 2023

Silence Therapeutics to Participate in September Investor Conferences

Business Wire September 6, 2023

Silence Therapeutics Reports Second Quarter 2023 Results

Business Wire August 16, 2023

Silence Therapeutics Achieves $4 Million in Research Milestone Payments from Hansoh Pharma Collaboration

Business Wire July 11, 2023

Silence Therapeutics to Present at the Jefferies Healthcare Conference

Business Wire May 31, 2023

Silence Therapeutics Reports First Quarter 2023 Results

Business Wire May 16, 2023

Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration

Business Wire May 4, 2023

Silence Therapeutics Completes Enrollment in Phase 2 Study of Zerlasiran (SLN360) in Subjects with Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events

Business Wire May 1, 2023

Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect Investor Conference

Business Wire April 25, 2023

Silence Therapeutics Announces Publication in Blood Demonstrating Role for Iron Regulation in Polycythemia Vera

Business Wire April 4, 2023